First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Kimberly VelthuisNaomi T JessurunThi D M NguyenJoep H G SchollJurriaan R G JansenJette A van LintLeanne J KossePeter M Ten KloosterHarald E VonkemanPublished in: Expert opinion on drug safety (2023)
Despite seemingly different nature and frequencies, ADRs are the second reason of treatment discontinuation for both bDMARDs. Furthermore, 2-, 5-, and 10-year drug survival is longer for ETN compared to ADA.